252056-70-5

Basic information

• Product Name: 5-Amino-3-methylpyridine-2-carbonitrile
• Synonyms: 2-Pyridinecarbonitrile,5-amino-3-methyl-(9CI);5-AMINO-3-METHYLPYRIDINE-2-CARBONITRILE,PURITY:95% MIN(HPLC);5-Amino-3-methylpyridine-2-carbonitrile;5-aMino-3-Methyl-2-Pyridinecarbonitrile;5-AMino-3-Methylpicolinonitrile;2-Pyridinecarbonitrile, 5-amino-3-methyl-
• CAS NO: 252056-70-5
• Molecular Formula: C₇H₇N₃
• Molecular Weight: 133.15
• Product Categories: PYRIDINE
• Mol File: 252056-70-5.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 370.308 °C at 760 mmHg
• Flash Point: 177.756 °C
• Appearance: /
• Density: 1.184 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.579
• Storage Temp.: 2-8°C(protect from light)
• PKA: 0.91±0.20(Predicted)
• CAS DataBase Reference: 5-Amino-3-methylpyridine-2-carbonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Amino-3-methylpyridine-2-carbonitrile(252056-70-5)
• EPA Substance Registry System: 5-Amino-3-methylpyridine-2-carbonitrile(252056-70-5)

Safety Data

• Hazardous Substances Data: 252056-70-5(Hazardous Substances Data)

Usage

General Description

5-Amino-3-methylpyridine-2-carbonitrile, also known as AMPC, is a chemical compound with the molecular formula C7H7N3. It is a derivative of pyridine and contains both amino and carbonitrile functional groups. AMPC is commonly used as an intermediate in the synthesis of pharmaceutical compounds and agrochemicals. Its unique structure and reactivity make it a valuable building block for the production of various organic molecules. AMPC is also of interest to researchers in the development of new drugs and materials due to its diverse chemical properties. Overall, 5-Amino-3-methylpyridine-2-carbonitrile plays an important role in organic synthesis and has applications in various industries.

InChI:InChI=1/C7H7N3/c1-5-2-6(9)4-10-7(5)3-8/h2,4H,9H2,1H3

Upstream product

• 65169-63-3 3-methyl-5-nitropyridine-2-carbonitrile 
• 7439-89-6 iron 
• 20970-75-6 2-cyano-3-methylpyridine 

Downstream Products

• 1332388-86-9 4-[7-(6-cyano-5-methyl-3-pyridyl)-6-oxo-8-thioxo-7,9-diazaspiro[4.4]nonan-9-yl]-2-fluoro-N-methylbenzamide 
• 228867-86-5 5-hydroxy-3-methylpyridine-2-carbonitrile 
• 1332388-85-8 4-[6-(6-cyano-5-methyl-3-pyridyl)-5-oxo-7-thioxo-6,8-diazaspiro[3.4]octan-8-yl]-2-fluoro-N-methylbenzamide 
• 1332388-87-0 3-methyl-5-[8-[4-(5-methyl-2-furyl)phenyl]-5-oxo-7-thioxo-6,8-diazaspiro[3.4]octan-6-yl]pyridine-2-carbonitrile 
• 1246383-20-9 5-Iodo-3-methyl-pyridine-2-carbonitrile 
• 156072-84-3 5-chloro-3-methylpyridine-2-carbonitrile 
• 218800-30-7 4-(3-bromo-10-methoxy-8-methyl-5,6-dihydro-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-piperidine-1-carboxylic acid ethyl ester 
• 218800-11-4 3-bromo-10-methoxy-8-methyl-11-(1-methyl-piperidin-4-ylidene)-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine 
• 218800-10-3 {5-bromo-3-[2-(3-methoxy-5-methyl-phenyl)-ethyl]-pyridin-2-yl}-(1-methyl-piperidin-4-yl)-methanone 
• 218799-96-3 5-bromo-3-[2-(3,5-dimethoxy-phenyl)-ethyl]-pyridine-2-carbonitrile 

Relevant articles and documents

Design and Synthesis of Clinical Candidate PF-06751979: A Potent, Brain Penetrant, β-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitor Lacking Hypopigmentation

A major challenge in the development of β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors for the treatment of Alzheimer's disease is the alignment of potency, drug-like properties, and selectivity over related aspartyl proteases such as Cathepsin D (CatD) and BACE2. The potential liabilities of inhibiting BACE2 chronically have only recently begun to emerge as BACE2 impacts the processing of the premelanosome protein (PMEL17) and disrupts melanosome morphology resulting in a depigmentation phenotype. Herein, we describe the identification of clinical candidate PF-06751979 (64), which displays excellent brain penetration, potent in vivo efficacy, and broad selectivity over related aspartyl proteases including BACE2. Chronic dosing of 64 for up to 9 months in dog did not reveal any observation of hair coat color (pigmentation) changes and suggests a key differentiator over current BACE1 inhibitors that are nonselective against BACE2 in later stage clinical development.

TETRAHYDROPYRANO[3,4-D][1,3]OXAZIN DERIVATIVES AND THEIR USE AS BACE INHIBITORS

The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula (I), wherein the variables R1, R2, R3, R4 and X are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES

The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula (I), and the variable R1 is as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.